Tumour suppressor p53/oncoprotein Mdm2 · PROTEIN-PROTEIN INTERACTION · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Tumour suppressor p53/oncoprotein Mdm2 shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P04637. Start with acute myeloid leukemia, then reuse UniProt P04637 as the stable protein anchor across project notes and exports.
Start with acute myeloid leukemia, then reuse UniProt P04637 as the stable protein anchor across project notes and exports.
Tumour suppressor p53/oncoprotein Mdm2 shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with acute myeloid leukemia because it currently carries late clinical support. Linked drugs include ALRIZOMADLIN, IDASANUTLIN, NAVTEMADLIN, SIREMADLIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCellular tumor antigen p53
Review this target as Tumour suppressor p53/oncoprotein Mdm2, mapped to UniProt P04637. ChEMBL maps the protein component as Cellular tumor antigen p53. Sequence length is 393 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tumour suppressor p53/oncoprotein Mdm2 as ChEMBL target CHEMBL1907611, mapped to UniProt P04637. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Tumour suppressor p53/oncoprotein Mdm2 is the right protein anchor across sources, using UniProt P04637 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acute myeloid leukemia is currently framed as late clinical support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Tumour suppressor p53/oncoprotein Mdm2 |
| Target Type | PROTEIN-PROTEIN INTERACTION |
| Organism | Homo sapiens |
| UniProt | P04637 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cellular tumor antigen p53 |
| UniProt Accession | P04637 |
| Component Type | Protein |
| Sequence Length | 393 aa |
Cellular tumor antigen p53
Review this target as Tumour suppressor p53/oncoprotein Mdm2, mapped to UniProt P04637. ChEMBL maps the protein component as Cellular tumor antigen p53. Sequence length is 393 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Tumour suppressor p53/oncoprotein Mdm2 shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.
Start review with acute myeloid leukemia because it currently carries late clinical support. Linked drugs include ALRIZOMADLIN, IDASANUTLIN, NAVTEMADLIN, SIREMADLIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5283210 | 10.89 | IC50 | 0.013 | Preclinical |
| CHEMBL5272028 | 10.72 | IC50 | 0.019 | Preclinical |
| CHEMBL3892862 | 10.21 | IC50 | 0.061 | Preclinical |
| CHEMBL3901716 | 10.19 | IC50 | 0.065 | Preclinical |
| CHEMBL3945756 | 10.17 | IC50 | 0.068 | Preclinical |
| CHEMBL3911501 | 10.16 | IC50 | 0.069 | Preclinical |
| CHEMBL3920430 | 10.15 | IC50 | 0.071 | Preclinical |
| CHEMBL3916525 | 10.12 | IC50 | 0.075 | Preclinical |
| CHEMBL4110580 | 10.11 | IC50 | 0.078 | Preclinical |
| CHEMBL3893972 | 10.1 | IC50 | 0.08 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 115 | 55 | 5.7 |
| protein format | 103 | 1,548 | 7.5 |
| assay format | 10 | 68 | 6.8 |
| tissue-based format | 2 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |